Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000880:Anthraquinones / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone; D012509:Sarcoma / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy; D013318:Stroke Volume / Q000187:drug effects; D013997:Time Factors
D000880:Anthraquinones; D000970:Antineoplastic Agents; D004317:Doxorubicin; D008942:Mitoxantrone